Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECIGEN, INC.PGEN · Entity 4356 | President and CEO | August 23, 2026 | August 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECIGEN, INC.
Report date August 23, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,779,521 |
Ending reported balance
After 2026-08-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-23 · Exercise / conversion · Acquired 20,833 · Balance 3,789,705 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Row 2 · 2026-08-23 · Tax withholding · Disposed 10,184 · Balance 3,779,521 F2: Represents the number of shares of Precigen common stock withheld by the Issuer to satisfy income tax withholding obligations in connection with the settlement of the RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 229,167 |
Reported balance
After 2026-08-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-23 · Exercise / conversion · Disposed 20,833 · Balance 229,167 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3: Represents 1/24 of the RSUs granted on June 26, 2025 that vested on August 23, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
F2: Represents the number of shares of Precigen common stock withheld by the Issuer to satisfy income tax withholding obligations in connection with the settlement of the RSUs.
F3: Represents 1/24 of the RSUs granted on June 26, 2025 that vested on August 23, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kinnate Biopharma Inc.
Report date April 03, 2024 · Filed April 05, 2024
Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.38 · Expires 2031-06-24 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-03 · Disposition to issuer · Disposed 40,501 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2033-06-12 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-03 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2032-06-13 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-03 · Disposition to issuer · Disposed 20,250 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 23, 2026 Filed Aug 25, 2026 21:24 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 20,833 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-26-012870 · ownership.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,167 Underlying: Common Stock · 20,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: Represents 1/24 of the RSUs granted on June 26, 2025 that vested on August 23, 2026. F3 · derivative.expiration_date: Represents 1/24 of the RSUs granted on June 26, 2025 that vested on August 23, 2026. Read SEC document |
| August 23, 2026 Filed Aug 25, 2026 21:24 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Tax withholdingCommon Stock | 10,184 | $7.20 | $73,324.80 |
DisclosureSEC source: 0000950103-26-012870 · ownership.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,779,521 F2 · shares: Represents the number of shares of Precigen common stock withheld by the Issuer to satisfy income tax withholding obligations in connection with the settlement of the RSUs. Read SEC document |
| August 23, 2026 Filed Aug 25, 2026 21:24 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 20,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-26-012870 · ownership.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,789,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:19 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionOption to Purchase Common Stock (Right to Buy) · Derivative | 346,836 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0000950103-26-009978 · ownership.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 500,164 Underlying: Common Stock · 346,836 shares Expires 2032-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:19 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 346,836 | $5.89 | $2,042,864.04 |
DisclosureSEC source: 0000950103-26-009978 · ownership.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,768,872 F1 · kind: Represents shares sold pursuant to the terms of a 10b5-1 plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.75 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:19 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 346,836 | $2.33 | $808,127.88 |
DisclosureSEC source: 0000950103-26-009978 · ownership.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,115,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:25 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 119,250 | $4.36 | $519,930.00 |
DisclosureSEC source: 0000950103-26-008168 · ownership.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,768,872 F1 · shares: Represents the number of shares of Precigen common stock sold pursuant to a sell-to-cover transaction to satisfy tax withholding obligations upon the vesting of restricted stock units on May 23, 2026. Read SEC document |
| May 23, 2026 Filed May 28, 2026 00:18 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-26-007842 · ownership.xml · derivative · entry 2 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: Represents 50% of the RSUs granted on June 26, 2025 that vested on May 23, 2026. The remaining RSUs will vest in equal quarterly installments for three years thereafter. F2 · derivative.expiration_date: Represents 50% of the RSUs granted on June 26, 2025 that vested on May 23, 2026. The remaining RSUs will vest in equal quarterly installments for three years thereafter. Read SEC document |
| May 23, 2026 Filed May 28, 2026 00:18 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 250,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-26-007842 · ownership.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,888,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:22 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 410,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-26-006044 · ownership.xml · derivative · entry 2 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest 25% on May 23, 2027 and in equal six-month installments for three years thereafter. F3 · derivative.expiration_date: The RSUs vest 25% on May 23, 2027 and in equal six-month installments for three years thereafter. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:22 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 1,366,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0000950103-26-006044 · ownership.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,366,000 Underlying: Common Stock · 1,366,000 shares Expires 2036-04-20 F1 · derivative.exercise_date: The options vest 25% on May 23, 2027 and in equal monthly installments for three years thereafter. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 23:27 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 321,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-26-004489 · dp243985_4-sabzevari.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 321,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested immediately upon the grant date. F2 · derivative.expiration_date: The RSUs vested immediately upon the grant date. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 23:27 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 321,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-26-004489 · dp243985_4-sabzevari.xml · derivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,100 Underlying: Common Stock · 321,100 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested immediately upon the grant date. F2 · derivative.expiration_date: The RSUs vested immediately upon the grant date. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 23:27 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 321,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-26-004489 · dp243985_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,638,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 23:47 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantPerformance Stock Units · Derivative | 825,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-25-011726 · dp234441_4-sabzevari.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 825,000 Underlying: Common Stock · 825,000 shares Expires not disclosed F1 · derivative.exercise_price: Represents the vesting of the second installment of performance stock units ("PSUs") originally granted on August 28, 2024 based on the achievement of the applicable performance condition for such installment. F2 · derivative.exercise_price: Each PSU is payable in a share of the Issuer's common stock or in a cash amount having an equivalent value. F1 · derivative.exercise_date: Represents the vesting of the second installment of performance stock units ("PSUs") originally granted on August 28, 2024 based on the achievement of the applicable performance condition for such installment. F2 · derivative.exercise_date: Each PSU is payable in a share of the Issuer's common stock or in a cash amount having an equivalent value. F1 · derivative.expiration_date: Represents the vesting of the second installment of performance stock units ("PSUs") originally granted on August 28, 2024 based on the achievement of the applicable performance condition for such installment. F2 · derivative.expiration_date: Each PSU is payable in a share of the Issuer's common stock or in a cash amount having an equivalent value. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 20:08 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-25-007990 · dp230754_4-sabzevari.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vest 50% on May 23, 2026 and in equal monthly installments for three years thereafter. F2 · derivative.expiration_date: The RSUs vest 50% on May 23, 2026 and in equal monthly installments for three years thereafter. Read SEC document |
| May 23, 2025 Filed May 27, 2025 23:21 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0000950103-25-006450 · dp229264_4-sabzevari.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2035-05-23 F1 · derivative.exercise_date: The options vest 50% on May 23, 2026 and in equal monthly installments for three years thereafter. Read SEC document |
| May 16, 2025 Filed May 16, 2025 23:52 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 1,079,137 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-25-006143 · dp228971_4-sabzevari.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,079,137 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vested in full on May 16, 2025. F3 · derivative.expiration_date: The RSUs vested in full on May 16, 2025. Read SEC document |
| May 16, 2025 Filed May 16, 2025 23:52 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Tax withholdingCommon Stock | 521,224 | $1.45 | $755,774.80 |
DisclosureSEC source: 0000950103-25-006143 · dp228971_4-sabzevari.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,317,022 F2 · shares: Represents the number of shares of common stock withheld by the Issuer to satisfy income tax withholding obligations in connection with the settlement of the RSUs. Read SEC document |
| May 16, 2025 Filed May 16, 2025 23:52 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 1,079,137 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-25-006143 · dp228971_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,838,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| April 17, 2025 Filed Apr 18, 2025 20:58 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 1,079,137 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-25-005063 · dp227908_4-sabzevari.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,079,137 Underlying: Common Stock · 1,079,137 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs will vest in full on May 16, 2025. F2 · derivative.expiration_date: The RSUs will vest in full on May 16, 2025. Read SEC document |
| January 29, 2025 Filed Feb 4, 2025 01:07 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Tax withholdingCommon Stock | 286,967 | $1.30 | $373,057.10 |
DisclosureSEC source: 0000950103-25-001481 · dp224422_4-sabzevari.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,759,109 F2 · shares: Represents the number of shares of Common Stock withheld by the Issuer to satisfy income tax withholding obligations in connection with the settlement of the PSUs. Read SEC document |
| January 29, 2025 Filed Feb 4, 2025 01:07 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantCommon Stock | 825,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-25-001481 · dp224422_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,046,076 F1 · shares: Represent shares of Precigen common stock ("Common Stock") issued on settlement of the first installment of performance stock units ("PSUs") originally granted on August 28, 2024 that vested based on the achievement of the applicable performance condition for such installment. Read SEC document |
| May 31, 2024 Filed May 31, 2024 23:03 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 1,803,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0000950103-24-007574 · dp212126_4-sabzevari.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,803,000 Underlying: Common Stock · 1,803,000 shares Expires 2034-05-31 F1 · derivative.exercise_date: The options vest 25% on May 31, 2025 and in equal monthly installments for three years thereafter. Read SEC document |
| April 05, 2024 Filed Apr 10, 2024 00:59 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 1,071,429 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-24-005095 · dp209631_4-sabzevari.xml · derivative · entry 4 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,071,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vested immediately upon the grant date. F3 · derivative.expiration_date: The RSUs vested immediately upon the grant date. Read SEC document |
| April 05, 2024 Filed Apr 10, 2024 00:59 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 1,071,429 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-24-005095 · dp209631_4-sabzevari.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,071,429 Underlying: Common Stock · 1,071,429 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vested immediately upon the grant date. F3 · derivative.expiration_date: The RSUs vested immediately upon the grant date. Read SEC document |
| April 05, 2024 Filed Apr 10, 2024 00:59 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Tax withholdingCommon Stock | 410,357 | $1.40 | $574,499.80 |
DisclosureSEC source: 0000950103-24-005095 · dp209631_4-sabzevari.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,221,076 F2 · shares: Represents the number of shares of common stock withheld by the Issuer to satisfy income tax withholding obligations in connection with the settlement of the RSUs. Read SEC document |
| April 05, 2024 Filed Apr 10, 2024 00:59 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 1,071,429 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-24-005095 · dp209631_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,631,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 20,250 | Not disclosed Strike: $8.38 | Not disclosed |
DisclosureSEC source: 0001415889-24-010426 · form4-04052024_040406.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,250 shares Expires 2032-06-13 F1 · price: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $3.48 | Not disclosed |
DisclosureSEC source: 0001415889-24-010426 · form4-04052024_040406.xml · derivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2033-06-12 F1 · price: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 40,501 | Not disclosed Strike: $24.38 | Not disclosed |
DisclosureSEC source: 0001415889-24-010426 · form4-04052024_040406.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,501 shares Expires 2031-06-24 F1 · price: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| August 25, 2023 Filed Aug 25, 2023 23:04 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 76,969 | $1.53 | $117,762.57 |
DisclosureSEC source: 0000950103-23-012774 · dp199184_4-sabzevari.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,560,004 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs pursuant to the terms of a 10b5-1 plan adopted by the reporting person. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the reporting person. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 23:04 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 141,587 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-23-012774 · dp199184_4-sabzevari.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 141,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: Represents 1/6 of the RSUs granted on March 24, 2023 that vested on August 23, 2023. F3 · derivative.expiration_date: Represents 1/6 of the RSUs granted on March 24, 2023 that vested on August 23, 2023. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 23:04 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 141,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-23-012774 · dp199184_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,636,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| August 18, 2023 Filed Aug 19, 2023 01:06 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 55,855 | $1.66 | $92,719.30 |
DisclosureSEC source: 0000950103-23-012318 · dp198761_4-sabzevari.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,495,386 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs pursuant to the terms of a 10b5-1 plan adopted by the reporting person. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the reporting person. Read SEC document |
| August 16, 2023 Filed Aug 19, 2023 01:06 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 141,587 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-23-012318 · dp198761_4-sabzevari.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,587 Underlying: Common Stock · 141,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: Represents 1/6 of the RSUs granted on March 24, 2023 that vested on August 16, 2023. The remaining RSUs vest on August 23, 2023. F3 · derivative.expiration_date: Represents 1/6 of the RSUs granted on March 24, 2023 that vested on August 16, 2023. The remaining RSUs vest on August 23, 2023. Read SEC document |
| August 16, 2023 Filed Aug 19, 2023 01:06 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 141,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-23-012318 · dp198761_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,551,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:24 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 41,436 | $1.44 | $59,667.84 |
DisclosureSEC source: 0000950103-23-011942 · dp198385_4-sabzevari.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,409,654 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs pursuant to the terms of a 10b5-1 plan adopted by the reporting person. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the reporting person. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 23:24 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 141,587 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-23-011942 · dp198385_4-sabzevari.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,173 Underlying: Common Stock · 141,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: Represents 1/6 of the RSUs granted on March 24, 2023 that vested on August 9, 2023. The remaining RSUs vest in two equal installments on each of August 16, 2023 and August 23, 2023. F3 · derivative.expiration_date: Represents 1/6 of the RSUs granted on March 24, 2023 that vested on August 9, 2023. The remaining RSUs vest in two equal installments on each of August 16, 2023 and August 23, 2023. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 23:24 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 141,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-23-011942 · dp198385_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,451,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| August 04, 2023 Filed Aug 4, 2023 23:05 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 52,870 | $1.10 | $58,157.00 |
DisclosureSEC source: 0000950103-23-011610 · dp198085_4-sabzevari.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,309,503 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs pursuant to the terms of a 10b5-1 plan adopted by the Reporting Person. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the reporting person. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 23:05 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 141,587 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-23-011610 · dp198085_4-sabzevari.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 424,760 Underlying: Common Stock · 141,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: Represents 1/6 of the RSUs granted on March 24, 2023 that vested on August 2, 2023. The remaining RSUs vest in three equal installments on each of August 9, 2023, August 16, 2023 and August 23, 2023. F3 · derivative.expiration_date: Represents 1/6 of the RSUs granted on March 24, 2023 that vested on August 2, 2023. The remaining RSUs vest in three equal installments on each of August 9, 2023, August 16, 2023 and August 23, 2023. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 23:05 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 141,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-23-011610 · dp198085_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,362,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 18:32 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.48 | $0.00 |
DisclosureSEC source: 0001209191-23-036867 · doc4.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-12 F1 · derivative.exercise_date: 1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 12, 2023 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date. Read SEC document |
| April 28, 2023 Filed May 2, 2023 21:53 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 1,732,300 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0000950103-23-006763 · dp193270_4-sabzevari.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,732,300 Underlying: Common Stock · 1,732,300 shares Expires 2033-04-28 F1 · derivative.exercise_date: The options vest 25% on April 28, 2024 and in equal monthly installments for three years thereafter. Read SEC document |
| March 24, 2023 Filed Mar 29, 2023 01:08 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 369,596 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000950103-23-004824 · dp191370_4-sabzevari.xml · derivative · entry 4 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369,596 Underlying: Common Stock · 369,596 shares Expires 2033-03-24 Read SEC document |
| March 24, 2023 Filed Mar 29, 2023 01:08 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 283,173 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-23-004824 · dp191370_4-sabzevari.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 566,347 Underlying: Common Stock · 283,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: Represents 1/3 of the RSUs granted on March 24, 2023 that vested immediately. F3 · derivative.expiration_date: Represents 1/3 of the RSUs granted on March 24, 2023 that vested immediately. Read SEC document |
| March 24, 2023 Filed Mar 29, 2023 01:08 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 849,520 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-23-004824 · dp191370_4-sabzevari.xml · derivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 849,520 Underlying: Common Stock · 849,520 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: 1/3 of the RSUs vested immediately upon the grant date, and the remaining RSUs vest in four equal installments on each of August 2, 2023, August 9, 2023, August 16, 2023 and August 23, 2023. F2 · derivative.expiration_date: 1/3 of the RSUs vested immediately upon the grant date, and the remaining RSUs vest in four equal installments on each of August 2, 2023, August 9, 2023, August 16, 2023 and August 23, 2023. Read SEC document |
| March 24, 2023 Filed Mar 29, 2023 01:08 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 283,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-23-004824 · dp191370_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,220,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 00:23 UTC | PRECIGEN, INC. PGEN · Entity 4356 | PurchaseCommon Stock | 22,857 | $1.75 | $39,999.75 |
DisclosureSEC source: 0000950103-23-001415 · dp187977_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 937,613 F1 · kind: The reporting person purchased shares of Precigen common stock ("Common Stock") in connection with the issuer's follow-on offering, which closed on January 27, 2023. The purchase price is the offering price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.